Accrued clinical and other research and development costs
-
-
-
23,355
Accrued manufacturing costs
-
-
-
5,002
Operating lease liability, current
-
-
-
9,164
Deferred research and development funding liability, current
-
-
-
22,580
Other accrued costs and current liabilities
78,276
69,776
95,021
4,942
Total current liabilities
90,083
110,156
98,351
90,146
Operating lease liability, less current portion
22,026
24,680
27,210
29,686
Finance lease liability, less current portion
5,479
5,508
5,532
5,554
Deferred research funding and development liability, less current portion
-
-
-
4,038
Liability related to the revenue participation right agreement
205,189
199,581
-
-
Total liabilities
322,777
339,925
131,093
129,424
Common stock, 0.01 par value 400,000,000 shares authorized as of june 30, 2026 and december 31, 2025 159,755,526 shares and 156,182,177 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
1,924
1,913
1,888
1,793
Additional paid-in capital
3,142,747
3,104,838
3,062,715
2,846,278
Accumulated other comprehensive income (loss)
-1,969
-682
682
1,101
Accumulated deficit
-2,307,524
-2,179,971
-2,051,524
-1,922,975
Total stockholders' equity
835,178
926,098
1,013,761
926,197
Total liabilities and stockholders equity
1,157,955
1,266,023
1,144,854
1,055,621
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.